

Pharmaceutical Pipeline – Key Events in 2021*

POTENTIAL APPROVALS US/EU			PLANNED SUBMISSIONS US/EU		POTENTIAL CLINICAL DATA PRESENTATIONS	
					Phase III	
✓	US	RYBREVANT (amivantamab) Non Small Cell Lung Cancer	✓	Submission Complete US	ciltacabtagene autoleucel (BCMA CAR-T)	✓ STELARA (ustekinumab) Crohn's Disease H2H vs. HUMIRA (SEAVUE)
			✓	EU	Relapsed refractory Multiple Myeloma	
	US	ciltacabtagene autoleucel (BCMA CAR-T) Relapsed refractory Multiple Myeloma	✓	EU	RYBREVANT (amivantamab) Non Small Cell Lung Cancer	✓ INVEGA HAFYERA (PP6M) Schizophrenia (ROUTE 6)
✓	US	DARZALEX (daratumumab)		US	IMBRUVICA (ibrutinib)	✓ IMBRUVICA (ibrutinib)
✓	EU	Amyloidosis (ANDROMEDA)		EU	Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)	Frontline chronic lymphocytic leukemia (I+V fixed duration) (GLOW)
✓	US	DARZALEX (daratumumab)	✓	US	XARELTO (rivaroxaban)	✓ ERLEADA (apalutamide)
✓	EU	Relapsed Refractory Multiple Myeloma w/PomDex			Pediatric VTE/CHD (Fontan)	Metastatic castrate sensitive prostate cancer- Final Analysis (TITAN)
✓	US	XARELTO (rivaroxaban) Infrainguinal revascular PAD	✓	EUA US	VAC31518	✓ DARZALEX (daratumumab)
			✓	cMAA EU	Janssen COVID-19 Vaccine	Multiple Myeloma (MAIA) Overall Survival Benefit
	US	XARELTO (rivaroxaban) Pediatric VTE/CHD (Fontan)			Phase II	
					✓ RYBREVANT (amivantamab) 2L NSCLC (CHRYSALIS)	
✓	EU	SPRAVATO (esketamine nasal spray) Major Depressive Disorder in a Psychiatric Emergency			milvexian (factor Xla) Total Knee Replacement (AXIOMATIC-TKR)	
✓	US	INVEGA HAFYERA (PP6M) Schizophrenia			✓ ciltacabtagene autoleucel (BCMA CAR-T) Multiple Myeloma (CARTITUDE-1 Longer term follow-up)	
✓	US	PONVORY (ponesimod)			teclistamab (BCMA/CD3) Relapsed refractory multiple myeloma (TECLIMMY1001)	
✓	EU	Relapsing forms of multiple sclerosis			✓ VAC18193 RSV Adult Vaccine (CYPRESS)	
✓	US	CABENUVA (rilpivrine long acting) HIV				
✓	US	UPTRAVI IV (selexipag) Pulmonary arterial hypertension				
✓	EUA US	VAC31518				
✓	cMAA EU	Janssen COVID-19 Vaccine				

*This information is accurate as of October 19, 2021 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

✓ = Achieved

